Several brokerages have updated their recommendations and price targets on shares of Alder BioPharmaceuticals (NASDAQ: ALDR) in the last few weeks:

  • 1/11/2018 – Alder BioPharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “
  • 1/9/2018 – Alder BioPharmaceuticals had its price target raised by analysts at BMO Capital Markets to $26.00. They now have an “outperform” rating on the stock.
  • 1/9/2018 – Alder BioPharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $29.00 price target on the stock, down previously from $32.00.
  • 1/4/2018 – Alder BioPharmaceuticals was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 1/4/2018 – Alder BioPharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/3/2018 – Alder BioPharmaceuticals had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $22.00 price target on the stock.
  • 12/29/2017 – Alder BioPharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 12/19/2017 – Alder BioPharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

Alder BioPharmaceuticals, Inc. (NASDAQ ALDR) traded down $0.10 on Friday, hitting $17.80. 785,839 shares of the company traded hands, compared to its average volume of 2,602,875. Alder BioPharmaceuticals, Inc. has a twelve month low of $8.60 and a twelve month high of $25.45. The firm has a market capitalization of $1,220.00, a PE ratio of -3.31 and a beta of 2.48.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.29. During the same quarter last year, the firm earned ($0.70) EPS. sell-side analysts anticipate that Alder BioPharmaceuticals, Inc. will post -5.14 earnings per share for the current year.

In other Alder BioPharmaceuticals news, insider Mark James Litton sold 16,520 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $12.33, for a total transaction of $203,691.60. Following the transaction, the insider now directly owns 116,452 shares of the company’s stock, valued at $1,435,853.16. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 10.60% of the company’s stock.

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Receive News & Ratings for Alder BioPharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.